




RealRate

PHARMACEUTICAL 2017

Sarepta Therapeutics Inc
Rank 126 of 308



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Sarepta Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sarepta Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 83% points. The greatest weakness of Sarepta Therapeutics Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 291%, being 46% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	373,476
Cost of Goods Sold	0
Intangible Assets	8,076
Liabilities, Current	75,422
Liabilities, Non-Current	5,949
Other Assets	4,751
Other Compr. Net Income	-9.0
Other Expenses	130
Other Liabilities	6,042
Other Net Income	-535
Other Revenues	5,421
Property and Equipment	37,801
Research and Development	188,272
Selling, General and Administrative Expense	83,749

Output Variable	Value in 1000 USD
Assets	424,104
Liabilities	87,413
Expenses	272,151
Revenues	5,421
Stockholders Equity	336,691
Net Income	-267,265
Comprehensive Net Income	-267,270
BaseVar	394,816
ECR before Limited Liability	182%
Economic Capital Ratio	291%